Dividend Sweden (DIV) Q2 2026 earnings summary

Executive summary

• Net sales for Q2 2026 were 1.9 MSEK, down from 2.3 MSEK year-over-year; H1 2026 net sales were 4.6 MSEK, down from 7.7 MSEK year-over-year.

• Net loss after tax for Q2 2026 was -1.4 MSEK (vs. -2.3 MSEK); H1 2026 net loss was -2.9 MSEK (vs. -0.3 MSEK).

• Result per share for H1 2026 was -0.03 SEK (vs. -0.00 SEK); equity ratio at period end was 91%.

• Portfolio company Evendo reported record results and strategic partnerships; Medicortex completed a reverse acquisition and was approved for continued listing.

• Directed share issue of 1.5 MSEK completed and investment made in OpenIR Nordic AB.

Financial highlights

• Operating income for H1 2026 was 4.6 MSEK, down from 7.7 MSEK year-over-year.

• Operating expenses for H1 2026 were 6.9 MSEK (vs. 7.9 MSEK), mainly from securities purchases.

• Operating result for H1 2026 was -2.3 MSEK (vs. 0.1 MSEK); result after financial items was -2.9 MSEK (vs. -0.3 MSEK).

• Cash and cash equivalents at period end were 0.2 MSEK (vs. 0.4 MSEK); equity at 63.7 MSEK.

• Net asset value per share at period end was 0.66 SEK (vs. 0.71 SEK).

Outlook and guidance

• Increased interest in investment and ownership distribution services; new business opportunities identified.

• Expectation of further positive developments from Evendo and potential strategic transactions in the coming quarter.